Sign up USA
Proactive Investors - Run By Investors For Investors

Amgen up after judge rules rivals must pull a competing cholesterol drug off the market

District Judge Sue Robinson in Delaware announced a ban on Regeneron and Sanofi from selling their cholesterol drug, Praluent on the grounds of patent infringement.
Drugs
However, Judge Robinson ordered that the ban not take effect for 30 days to give Sanofi and Regeneron time to appeal

Shares in Amgen Inc. (NASDAQ:AMGN) rose today after a US Federal judge ruled that two of the pharma firm's rivals must pull a competing cholesterol drug off the market.

Late yesterday, District Judge Sue Robinson in Delaware announced a ban on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and French firm Sanofi SA from selling their cholesterol drug, Praluent in the US on the grounds of patent infringement.

Amgen had sought a ban in an October 2014 lawsuit against the two firms claiming that Praluent, which lowers so-called "bad" cholesterol by blocking a protein known as PCSK9, infringed its patents related to that protein.

Blocking sales of Praluent, the judge said that "irreparable harm" had been done to Amgen's own cholesterol-lowering treatment, Repatha.

In early New York trading today, Amgen shares jumped 3% higher to $157, while shares in Regeneron dropped over 6% to $356.

However, Judge Robinson ordered that the ban not take effect for 30 days to give Sanofi and Regeneron time to appeal, which they said they would do.

In a statement today, Sanofi's executive vice president Karen Linehan said: “"It is our longstanding position that Amgen's patent claims are invalid and that the best interests of patients will be greatly disserved by an injunction preventing access to Praluent."

A jury found Amgen's patents were valid in March.

Commentators said the companies could still decide to reach a settlement that would give Amgen royalties on Praluent sales.

The US Food and Drug Administration approved Praluent and Repatha in 2015, and both are currently in final stage trials.



Register here to be notified of future AMGN Company articles
View full AMGN profile

Amgen Timeline

Newswire
August 26 2013

Related Articles

Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum
test tubes in a laboratory
March 22 2017
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use